Study identification

EU PAS number

EUPAS1000000776

Study ID

1000000776

Official title and acronym

Enzalutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A Non-Interventional Center-based Chart Review in Europe (ENHANCE)

DARWIN EU® study

No

Study countries

France
Germany

Study description

Given the clinical significance of mHSPC and the availability of multiple ARPIs for treatment, there remains a need to validate and expand upon existing findings through realworld studies in European settings. Therefore, the objectives of this study are twofold: (1) to assess the feasibility and appropriateness of comparing outcomes among mHSPC patients treated with ARPIs, based on baseline characteristics and outcome data availability; and (2) if deemed feasible, to compare real-world outcomes among mHSPC patients treated with different ARPIs based on a center-based chart review study in Europe

Study status

Planned
Research institutions and networks

Institutions

Astellas Pharma Europe Ltd.

Contact details

Thomas McLean

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Astellas Pharma Europe Ltd
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable